Alkahest Announces

Update research Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration SAN CARLOS, Calif., May 14, 2018 /PRNewswire/ — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on...

Wet AMD trial meets primary safety objective

Wet AMD trial meets primary safety objective By Life Scientist Staff Opthea (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has met the primary objective of safety in the dose escalation of its ongoing first-in-human clinical...
On